There are currently 52 active clinical trials seeking participants for Glioblastoma Multiforme research studies. The states with the highest number of trials for Autism participants are California, Texas, New York and Ohio.
Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma
NCT04528680
Recruiting
Paclitaxel is among the most active agents against glioblastoma in preclinical models. However, its clinical use has been hampered by the blood-brain barrier (BBB). In this trial we will implant a novel device with 9 ultrasound emitters allowing to temporarily and reversibly open the BBB immediately prior to chemotherapy infusion with albumin-bound paclitaxel. In the phase 1 component, increasing doses of chemotherapy will be delivered as long deemed safe based on the prior patient not experien... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/13/2023
Locations: Northwestern Memorial Hospital, Chicago, Illinois
Conditions: Glioblastoma, Gliosarcoma, GBM, Glioblastoma Multiforme, Glioblastoma, IDH-wildtype, Recurrent Glioblastoma
Register for Updates
Spatiotemporal Dimensions of Metabolism in Autochthonous Tumors of GBM Patients
NCT06054529
Recruiting
To learn how altered metabolism in GBM causes tumor growth and resistance to drug therapy. In this pilot research study, we will dose GBM patients with a form of nicotinamide (a natural vitamin) that we can track. The nicotinamide will be converted to methyl nicotinamide (MeNAM) in the tumor. We will measure how fast the nicotinamide is converted to methyl nicotinamide. We believe that the speed of this chemical reaction in the tumor (fast versus slow) may be correlated with GBM aggressiveness
Gender:
All
Ages:
18 years and above
Trial Updated:
11/06/2023
Locations: AdventHealth Translational Research Institute, Orlando, Florida
Conditions: Glioblastoma Multiforme
Register for Updates
Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells
NCT06059690
Recruiting
The purpose of this project is to validate a new combined MRI and PET imaging technique as a biomarker or measure of glycolysis in brain tumors. To accomplish this, the investigators propose obtaining image-guided measures of tissue pH and biopsied tissue in tumor areas selected for bulk resection surgery. Investigators will then correlate the imaging measurements with pH, RNA expression, protein expression, and bioenergetics measurements of key glycolytic enzymes.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/24/2023
Locations: University of California at Los Angeles, Los Angeles, California
Conditions: Glioblastoma Multiforme, Glycolytic Index, Epidermal Growth Factor Receptor
Register for Updates
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
NCT03175224
Recruiting
To assess: efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring wild-type MET with overexpression of HGF and MET efficacy of APL-101 as an add-on therapy to EGFR inhibitor for the treatment of NSCLC harboring EGFR activating mutations and developed acquired resistanc... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/19/2023
Locations: Loma Linda University Medical Center, Loma Linda, California +90 locations
Conditions: Advanced Cancer, Renal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, NSCLC, Lung Cancer, Brain Tumor, Glioblastoma Multiforme, Solid Tumors, EGFR Gene Mutation, MET Amplification, HGF, Thyroid Cancer, Pancreatic Cancer, Colon Cancer, MET Alteration, MET Fusion, Exon 14 Skipping
Register for Updates
Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)
NCT05979064
Recruiting
This single center, single arm, open-label, phase I study will assess the safety of laparoscopically harvested autologous omentum, implanted into the resection cavity of recurrent glioblastoma multiforme (GBM) patients.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/19/2023
Locations: Lenox Hill Brain Tumor Center, New York, New York
Conditions: Glioma, Glioma, Malignant, Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme of Brain, GBM, Brain Cancer, High Grade Glioma
Register for Updates
Study of Pamiparib in Newly Diagnosed and rGBM
NCT04614909
Recruiting
This is an open-label, single-center Phase 0/2 study that will enroll up to 30 participants with newly diagnosed (N=12) and recurrent glioblastoma (N=18). The trial will be composed of a Phase 0 component (subdivided into Arm A, Arm B, and Arm C), and an Exploratory Phase 2 component. Participants with tumors demonstrating a PK response in the Phase 0 component of the study will graduate to an exploratory Phase 2 component that combines therapeutic dosing of pamiparib plus fractionated radiother... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
09/15/2023
Locations: St. Joseph's Hospital and Medical Center, Phoenix, Arizona
Conditions: Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme, Adult
Register for Updates
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
NCT03596086
Recruiting
Study to assess the safety and efficacy of HSV-tk (gene therapy), valacyclovir, radiotherapy and chemotherapy in recurrent glioblastoma multiforme.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/30/2023
Locations: Houston Methodist Neurological Institute, Houston, Texas
Conditions: Glioblastoma Multiforme, Astrocytoma, Grade III
Register for Updates
A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2
NCT03152318
Recruiting
This research study is evaluating an investigational drug, an oncolytic virus called rQNestin34.5v.2. This research study is a Phase I clinical trial, which tests the safety of an investigational drug and also tries to define the appropriate dose of the investigational drug as a possible treatment for this diagnosis of recurrent or progressive brain tumor.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/07/2023
Locations: Johns Hopkins University Medical Center, Baltimore, Maryland +4 locations
Conditions: Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma, Oligodendroglioma, Anaplastic Oligodendroglioma of Brain (Diagnosis), Mixed Oligo-Astrocytoma, Ependymoma, Ganglioglioma, Pylocytic/Pylomyxoid Astrocytoma, Brain Tumor, Glioma, Brain Cancer, Glioblastoma, Glioblastoma Multiforme
Register for Updates
Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma
NCT05954858
Recruiting
This single center, single arm, open-label, phase 2 study will assess the safety and efficacy of a pedicled temporoparietal fascial (TPF) or pericranial flap into the resection cavity of newly diagnosed glioblastoma multifome (GBM) patients. The objective of the Phase 2 study is to demonstrate that this surgical technique is safe and effective in a human cohort of patients with resected newly diagnosed AA or GBM and may improve progression-free survival (PFS) and overall survival (OS).
Gender:
All
Ages:
18 years and above
Trial Updated:
08/01/2023
Locations: Lenox Hill Brain Tumor Center, New York, New York
Conditions: Glioma, Malignant, Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme, Adult, High Grade Glioma, GBM, Brain Cancer
Register for Updates
Loupe-Based Intraoperative Fluorescence Imaging
NCT04780009
Recruiting
Glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA) are the most common primary malignant brain tumors. Survival of patients with these brain tumors is directly related to the extent of resection. Consequently, a great deal of effort has been directed at developing techniques and technologies that allow more extensive, safe resections. This study will test a loupe-based wearable device in the clinical setting and compare its accuracy with a large operative microscope to identify tumor... Read More
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
07/10/2023
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Glioblastoma Multiforme, Anaplastic Astrocytoma
Register for Updates
Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme
NCT02177578
Recruiting
In this study patients will be treated with 6 weeks of radiation therapy plus temozolomide chemotherapy according to the standard of care. However, the radiation treatment plan will be modified to deliver an higher than routine radiation dose to the subventricular zone which is an area of the brain that contains stem cells that some scientists believe may contribute to glioblastoma recurrence. The purpose of the study is to see if the tumor is controlled for a longer period of time in patients t... Read More
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
05/30/2023
Locations: Sibley Memorial Hospital, Washington, District of Columbia +2 locations
Conditions: Glioblastoma Multiforme
Register for Updates
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
NCT05271240
Recruiting
Primary brain cancer kills up to 10,000 Americans a year. These brain tumors are typically treated by surgery, radiation therapy and chemotherapy, either individually or in combination. Present therapies are inadequate, as evidenced by the low 5-year survival rate for brain cancer patients, with median survival at approximately 12 months. Glioma is the most common form of primary brain cancer, afflicting approximately 7,000 patients in the United States each year. These highly malignant cancers... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/26/2023
Locations: Lenox Hill Brain Tumor Center, New York, New York
Conditions: Glioblastoma, Glioblastoma Multiforme, Glioma, Malignant, GBM, Brain Cancer, Glioblastoma, IDH-wildtype, Glioblastoma Multiforme, Adult
Register for Updates